ClinicalTrials.gg
CompletedNCT00334958Updated Jun 14, 2021Results posted

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

A Phase 3 interventional study of Placebo and Rufinamide in Epilepsy, sponsored by Eisai Inc.. Completed at 77 sites in United States. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2006, registered Jun 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Epilepsy by Eisai Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Epilepsy · Eisai Co., Ltd..

Enrollment
5th of 42
356 · median 83
Started
2006
with 6 others
Phase 3
17 of 51
none open now
Registered
8th of 51
by date

Among the 51 studies in Epilepsy by Eisai Co., Ltd., this one is the 5th largest by enrollment of the 42 interventional ones that give a count, is one of 7 that started in 2006, is one of 17 in phase 3, and was the 8th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 51 studies in Epilepsy by Eisai Co., Ltd. is open now. The open studies under Epilepsy, anywhere →

Who these studies take

Of the 283 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 138 take children under 18; 55 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 51 studies in Epilepsy by Eisai Co., Ltd. as a file.
02

Study summary

To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs).

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients between 12 and 80 years of age, inclusive.
  2. Diagnosis of epilepsy with partial-onset seizures with or without secondarily generalized seizures according with the International League Against Epilepsy Classification of Epileptic Seizures (1981). Diagnosis should have been established by clinical history, electroencephalogram (EEG) and computed tomography/magnetic resonance imaging (CT/MRI) of the brain performed within the last 10 years and consistent with localization-related epilepsy.
  3. Non-controlled partial seizures despite having been treated with at least two different antiepileptic drugs (given concurrently or sequentially) for at least two years.
  4. Patient willing to participate and written consent signed by patient or legal guardian prior to entering the study or undergoing any study procedures. If the written consent is provided by a legal guardian because the patient is unable to do so, assent of the patient must also be obtained.
  5. Reliability and willingness of patients to make themselves available for the study period, and ability to record seizures and report adverse events themselves or have a caregiver who can record seizures and report adverse events.
  6. Female patients of non- by reason of surgery, radiation, or menopause (at least one year post onset); or of childbearing potential using two approved methods of (such as an intrauterine device [IUD], implant, oral contraceptive, or barrier method plus spermicide). Use of a low-dose estrogen oral contraceptive ("minipill") alone will not be permitted. Female patients of childbearing potential must have a confirmed negative serum pregnancy test at screening and a negative urine pregnancy test prior to randomization, and agree to continue to use two approved methods of contraception through the follow-up visit (Visit 8) or for 30 days after their final dose of study medication, whichever is longer.
  7. At least six seizures during the prospective Baseline Phase (56 days) with no 21-day seizure-free periods. Simple partial seizures without motor signs will not be included in determining this criterion.
  8. Current treatment with a maximum of three approved antiepileptic drugs, and no evidence of non-compliance with ongoing AED therapy.
  9. Stable dose(s) of the same AED(s) for one month prior to screening.
  10. If using a vagal nerve stimulator, it must have been implanted for at least six months prior to randomization. Stimulator parameters may not be changed for at least one month prior to screening or thereafter during the study. Magnet use will be allowed, but must be documented throughout the study. A vagal nerve stimulator will not be counted as an AED for the purpose of inclusion into the trial.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Participation in a study involving administration of an compound within one month of Visit 1 (Screening), or within five half-lives of the previous investigational compound, whichever is longer; or any prior exposure to rufinamide.
  2. Presence of non-motor simple partial seizures only.
  3. Presence of generalized epilepsies or seizures, such as absences, myoclonic epilepsies, Lennox-Gastaut syndrome.
  4. History of status epilepticus in the past year or seizure clusters where individual seizures cannot be counted.
  5. Evidence of disease (cardiac, respiratory, gastrointestinal, hepatic, hematologic or renal disease, etc.) that in the opinion of the Investigator could affect the patient's safety or trial conduct.
  6. Clinically significant abnormality.
  7. Patients with a diagnosis of major active psychiatric disease will be excluded from the study. However, those patients who are only taking a stable dose of either a selective serotonin reuptake inhibitor (SSRI) antidepressant drug or a serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressant drug for a diagnosed depressive disorder can be included as long as they have been on the SSRI or SNRI for a period of two months or longer before randomization. Other antidepressant medications will not be allowed.
  8. Progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors.
  9. Occurrence of psychogenic seizures in the previous year.
  10. History of drug abuse and/or positive finding on urinary drug screening, other than prescribed medication
  11. History of alcohol abuse in the past two years.
  12. History of suicide attempt within the previous 10 years.
  13. Multiple drug allergies (dermatological, hematological or organ toxicity) or more than one severe drug reaction(s).
  14. Concomitant use of felbamate or use of felbamate within two months prior to Visit 1.
  15. Frequent need of rescue benzodiazepines (more than once a month).
  16. Patients with a known to rufinamide, triazole derivatives, or to any used in the formulation.
  17. Concomitant use of vigabatrin. Patients who took vigabatrin in the past must be off vigabatrin for at least five months prior to Visit 1 and must not have evidence of a clinically significant abnormality in a visual perimetry test.
  18. All Patients with a diagnosis of Congenital Short Syndrome. Patients with a family history of Congenital Short QT Syndrome may be excluded on the basis of the Investigator's clinical judgment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
356 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    For 12-day Titration Phase and 12 week Maintenance Phase, placebo tablets matching to rufinamide 400 mg oral tablets will be administered according to the same regimen scheme as described for rufinamide. For 12-day Titration Phase, 1 matching placebo tablet will be administered twice daily and increased by 1 tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily.

    Drug: Placebo

  • Active comparator
    Rufinamide

    For the 12-day Titration Phase, rufinamide will be administered orally in doses starting with 400 milligram (mg) twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the 12 week Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).

    Drug: Rufinamide

Interventions

  • DrugPlacebo

    For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.

  • For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).

    Also known as: E2080, BANZEL

06

What researchers measure

Primary outcomes

  1. Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase

    Seizure data was collected via patient diary, which was used to record daily seizure count and type. Intent-to-treat (ITT) population: All randomized participants who had baseline Patient Seizure Diary data and had at least completed the titration period.

    Time frame: Baseline, Days 13 to 96

Secondary outcomes

  1. Percentage of Participants With 50% or Greater Reduction in Total Partial Seizure Frequency Per 28 Days During the Maintenance Phase Relative to the Baseline Phase

    Seizure data was collected via patient diary, which was used to record daily seizure count and type.

    Time frame: Baseline, Days 13 to 96

  2. Log10 Transformed Total Partial Seizure Frequency Per 28 Days During the Baseline Phase and Maintenance Phase

    Total partial seizure frequencies per 28 days during the double-blind Maintenance and Baseline Phases were transformed using logarithms to the base 10 (log10), because it was expected from previous studies that the results would not be normally distributed.

    Time frame: Days 13 to 96

  3. Reduction From Baseline in Total Partial Seizure Frequency Rate (RRATIO) During Maintenance Phase

    RRATIO= 100\*(T-B)/(T+B) where T= total seizure frequency per 28 days during the Maintenance Phase, and B=total seizure frequency per 28 days during the Baseline Phase.

    Time frame: Baseline, Days 13 to 96

07

Results

Posted Feb 5, 2013

Participant flow

Participant flow — Overall Study
MilestoneRufinamidePlacebo
Started176180
Completed139156
Not completed3724
Withdrew: Medication noncompliance03
Withdrew: Protocol violation22
Withdrew: Request of the investigator or sponsor01
Withdrew: Withdrawal by subject74
Withdrew: Adverse event2712
Withdrew: Other12

Outcome measures

PrimaryPercentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase

Seizure data was collected via patient diary, which was used to record daily seizure count and type. Intent-to-treat (ITT) population: All randomized participants who had baseline Patient Seizure Diary data and had at least completed the titration period.

Time frame:
Baseline, Days 13 to 96
Reported as:
Median · Percentage change
Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase
Percentage changeRufinamidePlacebo
Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase-23.25 (-100.0 to 725.6)-9.80 (-100.0 to 864.3)
SecondaryPercentage of Participants With 50% or Greater Reduction in Total Partial Seizure Frequency Per 28 Days During the Maintenance Phase Relative to the Baseline Phase

Seizure data was collected via patient diary, which was used to record daily seizure count and type.

Time frame:
Baseline, Days 13 to 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With 50% or Greater Reduction in Total Partial Seizure Frequency Per 28 Days During the Maintenance Phase Relative to the Baseline Phase
Percentage of ParticipantsRufinamidePlacebo
Percentage of Participants With 50% or Greater Reduction in Total Partial Seizure Frequency Per 28 Days During the Maintenance Phase Relative to the Baseline Phase32.514.3
SecondaryLog10 Transformed Total Partial Seizure Frequency Per 28 Days During the Baseline Phase and Maintenance Phase

Total partial seizure frequencies per 28 days during the double-blind Maintenance and Baseline Phases were transformed using logarithms to the base 10 (log10), because it was expected from previous studies that the results would not be normally distributed.

Time frame:
Days 13 to 96
Reported as:
Mean · Seizures per 28-days (log-transformed)
Log10 Transformed Total Partial Seizure Frequency Per 28 Days During the Baseline Phase and Maintenance Phase
Seizures per 28-days (log-transformed)RufinamidePlacebo
Log10 Transformed Total Partial Seizure Frequency Per 28 Days During the Baseline Phase and Maintenance Phase0.98 ± 0.6751.13 ± 0.520
SecondaryReduction From Baseline in Total Partial Seizure Frequency Rate (RRATIO) During Maintenance Phase

RRATIO= 100\*(T-B)/(T+B) where T= total seizure frequency per 28 days during the Maintenance Phase, and B=total seizure frequency per 28 days during the Baseline Phase.

Time frame:
Baseline, Days 13 to 96
Reported as:
Mean · RRATIO
Reduction From Baseline in Total Partial Seizure Frequency Rate (RRATIO) During Maintenance Phase
RRATIORufinamidePlacebo
Reduction From Baseline in Total Partial Seizure Frequency Rate (RRATIO) During Maintenance Phase-18.76 ± 37.841-6.90 ± 24.869

Adverse events

Collected over All AEs were collected throughout the study from the time of consent to follow-up visit or 30 days after study drug discontinuation, whichever was longer (up to approximately 3 years and 3 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rufinamide0/176 (0%)6/176 (3.4%)101/176 (57.4%)
Placebo0/180 (0%)7/180 (3.9%)66/180 (36.7%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventRufinamidePlacebo
ConvulsionNervous system disorders2/1762/180
NauseaGastrointestinal disorders1/1760/180
VomitingGastrointestinal disorders1/1760/180
Road traffic accidentInjury, poisoning and procedural complications1/1760/180
Weight decreasedInvestigations1/1760/180
Complex partial seizuresNervous system disorders1/1761/180
Coordination abnormalNervous system disorders1/1760/180
LethargyNervous system disorders1/1760/180
Transient ischaemic attackNervous system disorders1/1760/180
ContusionInjury, poisoning and procedural complications1/1760/180
Most frequent other events
Most frequent other events
EventRufinamidePlacebo
DizzinessNervous system disorders47/17615/180
HeadacheNervous system disorders29/17623/180
FatigueGeneral disorders27/17618/180
NauseaGastrointestinal disorders22/1769/180
SomnolenceNervous system disorders22/17613/180
Upper respiratory tract infectionInfections and infestations6/17615/180
DiplopiaEye disorders14/1762/180
VomitingGastrointestinal disorders13/1769/180
ContusionInjury, poisoning and procedural complications9/1765/180

Baseline characteristics

Age, Customized
Age, Customized(participants)RufinamidePlaceboTotal
12 to < 18 years152136
18 to <65 years155153308
>=65 years6612
Sex: Female, Male
Sex: Female, Male(Participants)RufinamidePlaceboTotal
Female9297189
Male8483167
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RufinamidePlaceboTotal
Black141933
White145140285
Hispanic131427
Native American022
Asian/Pacific Islander426
Other033
08

Study locations

77 sites
  • University of South Alabama Medical Center
    Mobile, Alabama 36693, United States
  • Neurology Clinic PC
    Northport, Alabama 35476, United States
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • Mayo Clinic Epilepsy and Neurology
    Phoenix, Arizona 85054, United States
  • University of Arizona, Dept. of Neurology
    Tucson, Arizona 85724-5023, United States
  • Clinical Trials, Inc
    Little Rock, Arkansas 72205, United States
  • Neuro-Pain Medical Center, Inc.
    Fresno, California 93710, United States
  • Neurology Center
    Oceanside, California 92056, United States
  • California Pacific Epilepsy
    San Francisco, California 94115, United States
  • Georgetown University Hospital, Dept. of Neurology
    Washington, District of Columbia 20007, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Bradenton Research Center
    Bradenton, Florida 34205, United States
  • University of Florida, Dept. of Neurology
    Gainesville, Florida 32611, United States
  • University of Florida, The Neuroscience Institute at Shands
    Jacksonville, Florida 32209, United States
  • Pediatric Neurologists of Palm Beach
    Loxahatchee Groves, Florida 33470, United States
  • Nemours Children's Clinic
    Orlando, Florida 32835, United States
  • Pediatric Neurology - PA
    Orlando, Florida, United States
  • Bay Medical Center
    Panama City, Florida 32405, United States
  • University of Southern Florida, Dept. of Neurology
    Tampa, Florida 33606, United States
  • Child Neurology Associates, PC
    Atlanta, Georgia 30342, United States
  • Medical College of Georgia, Dept. of Neurology
    Augusta, Georgia 30912, United States
  • Medical Associates of North Georgia
    Canton, Georgia 30114, United States
  • The Queen's Medical Center
    Honolulu, Hawaii 96813, United States
  • Children's Memorial Hospital, Northwest University
    Chicago, Illinois 60614-3394, United States
  • Advocate Hope Children's Hospital
    Oak Lawn, Illinois 60453, United States
  • Advocate Lutheran General Children's Hospital
    Park Ridge, Illinois 60068, United States
  • Southern Illinois University Neurology and Pharmacology
    Springfield, Illinois 62794-9643, United States
  • Mcfarland Clinic
    Ames, Iowa 50010, United States
  • Via Christi Comprehensive Epilepsy Center
    Wichita, Kansas 67214, United States
  • University of Kentucky, Dept. of Neurology
    Lexington, Kentucky 40536-0284, United States
  • John Hopkins Hospital, Dept. of Neurology
    Baltimore, Maryland 21287, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • Boston University Medical Center, Dept. of Neurology
    Boston, Massachusetts 02118, United States
  • University of Massachusetts, Neurology Associates
    Hopedale, Massachusetts 01747, United States
  • University of Minnesota, Dept. of Neurology
    Minneapolis, Minnesota 55455, United States
  • Minnesota Epilepsy Group, PC
    Saint Paul, Minnesota 55102, United States
  • Ronald Schwartz, M.D.
    Hattiesburg, Mississippi 39401, United States
  • Hattiesburg Clinic
    Hattiesburg, Mississippi, United States
  • The Comprehensive Epilepsy Care Center for Children and Adults
    Chesterfield, Missouri 63017, United States
  • Saint Louis University
    Saint Louis, Missouri 63110, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Saint John's Medical Research
    Springfield, Missouri 65807, United States
  • Dartmouth Medical School Neuroscience Center
    Lebanon, New Hampshire 03756-0001, United States
  • Montefiore Medical Center, Albert Einstein College of Medicine
    Bronx, New York 10467, United States
  • Five Towns Neuroscience Research
    Lawrence, New York 11559, United States
  • New York University Medical Centre, Comprehensive Epilepsy Center
    New York, New York 10016, United States
  • Weill Cornell Medical Center, Comprehensive Epilepsy Center
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Asheville Neurology Specialists, PA
    Asheville, North Carolina 28806, United States
  • University of North Carolina at Chapel Hill, Dept. of Neurology
    Chapel Hill, North Carolina 27599-7025, United States
  • Duke Health Center at Morreene Road
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Foundation, Dept. of Neurology
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Medical University of Ohio at Toledo, Dept. of Neurology
    Toledo, Ohio 43614, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Blair Medical Associates, Inc.
    Altoona, Pennsylvania 16602, United States
  • Hospital of The University of Pennsylvania
    Philadelphia, Pennsylvania 19104-4204, United States
  • Hospital of the University of Pennsylvania, Dept. of Neurology
    Philadelphia, Pennsylvania 19104-4283, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh - Dept of Pediatrics
    Pittsburgh, Pennsylvania, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Mid-South Physicians Group, PLLC
    Germantown, Tennessee 38138, United States
  • University of Tennessee Health Sciences Center, Dept. of Neurology
    Memphis, Tennessee 38105, United States
  • UT Medical Group
    Memphis, Tennessee, United States
  • Access Clinical Trials, Inc
    Nashville, Tennessee 37203, United States
  • Neurological Clinic of Texas, PA
    Dallas, Texas 75230, United States
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390-9034, United States
  • Texas Tech University Health Sciences Center, Dept. of Neuropsychiatry
    El Paso, Texas 79905, United States
  • University of Texas - Dept of Neurology
    Houston, Texas, United States
  • Baylor Medical Center of Irving
    Irving, Texas 75061, United States
  • Epilepsy and Neurodevelopment, Inc.
    West Jordan, Utah 84088, United States
  • University of Vermont, College of Medicine, Clinical Neurophysiology Lab
    Burlington, Vermont '05401, United States
  • Fletcher Allen Healthcare
    Burlington, Vermont, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298-0211, United States
  • University of Washington, Harborview Medical Center, Regional Epilepsy Center
    Seattle, Washington 98105, United States
  • University of Wisconsin, Dept. of Neurology
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Panebianco M, Prabhakar H, Marson AG. Rufinamide add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020 Nov 8;11(11):CD011772. doi: 10.1002/14651858.CD011772.pub3. PubMed 33179247 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2006 to primary completion in May 2009, 39 months.

Results were first posted in Feb 2013, 3 years 8 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 39 months is below that.

Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2006
First posted
Jun 8, 2006
StartActual
Feb 13, 2006
Primary completionActual
May 20, 2009
CompletionActual
May 20, 2009
Results first posted
Feb 5, 2013
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00334958
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 8, 2006
Start date
Feb 13, 2006
Primary completion
May 20, 2009
Completion
May 20, 2009
Results posted
Feb 5, 2013
Last update
Jun 14, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rufinamide

Start the discussion